Therapeutic Purpose

Butopan is classified as an antispasmodic medication. It is primarily used to manage symptoms caused by spasms, or involuntary muscle contractions, within the smooth muscles of the digestive, urinary, and biliary systems. By facilitating the relaxation of these muscles, the medication helps to alleviate the physical discomfort and cramping associated with various abdominal and pelvic conditions.

Main Uses

Gastrointestinal Spasms

The medication is frequently used to address cramping and pain related to the stomach and intestines. This includes the management of discomfort associated with irritable bowel syndrome (IBS) and other functional gastrointestinal disorders where muscle overactivity leads to pain.

Biliary Colic

Butopan is indicated for the relief of biliary colic, which is the pain resulting from spasms in the bile ducts. It helps to relax the biliary tract, easing the passage or pressure issues that cause acute abdominal distress.

Genitourinary Tract Spasms

The drug is also used to treat spasms in the genitourinary system. This includes the relief of bladder cramps and renal colic—intense pain caused by spasms in the ureters, often associated with kidney stones. In women, it may also be used to mitigate the smooth muscle contractions associated with painful menstrual periods (dysmenorrhea).

Benefits and Effects

• Targeted Relaxation: The primary benefit of Butopan is its ability to act directly on the smooth muscle of the internal organs without significantly affecting the central nervous system.
• Symptom Relief: By reducing the intensity and frequency of muscle contractions, it provides relief from sharp, cramping pain and steady aches in the abdomen and pelvic region.
• Support for Diagnostic Procedures: In some clinical settings, the medication is used to relax the organs of the digestive or urinary tract to facilitate clearer imaging or smoother passage of instruments during diagnostic examinations.

Official Eligibility Profile: Hyoscine Butylbromide

Regulatory documents define specific populations who are permitted to use Butopan (Hyoscine Butylbromide) and those for whom use is strictly contraindicated. The medicine is established for use in adults, but its oral tablet formulation is not recommended for children under 6 years of age in most jurisdictions.

Contraindicated Populations (Must Not Use)

Category	Contraindication
Cardiovascular/Ocular	Untreated narrow-angle glaucoma, pre-existing tachycardia (for injection).
Neuromuscular	Myasthenia gravis.
Gastrointestinal/Genitourinary	Obstructive conditions (e.g., mechanical stenosis, paralytic or obstructive ileus, megacolon, prostatic hypertrophy with urinary retention).

Restricted and Life-Stage Eligibility

Use is not recommended during pregnancy or lactation due to limited or insufficient human safety data provided in regulatory submissions, making the risk status for the fetus or infant not established. Caution is also required in patients with certain cardiac conditions (like cardiac failure or coronary heart disease) due to the drug’s potential to increase heart rate. Patients with rare hereditary conditions such as fructose intolerance must not take the coated tablet formulation.

Interactions with other medicines and products

Butopan (Hyoscine Butylbromide) interaction patterns are officially documented to involve pharmacodynamic augmentation, effects on gastrointestinal motility, and administration route restrictions, as detailed in regulatory prescribing information. The primary pharmacodynamic interaction involves the intensification of the drug’s anticholinergic effect when co-administered with other agents possessing similar properties. These include tri- and tetracyclic antidepressants, antihistamines, certain antipsychotics, quinidine, amantadine, and disopyramide.

Butopan can impact the absorption of other medicines. Specifically, its effect on reducing gastrointestinal motility may delay the systemic absorption and pharmacological effects of other concurrently taken oral medications. Conversely, the absorption of Butopan itself may be reduced by co-administration with antacids or adsorbent antidiarrheal drugs, necessitating that Butopan be administered at least one hour before these products.

A significant restriction applies to the injectable form: it is prohibited for intramuscular use in patients receiving anticoagulant drugs due to the documented risk of intramuscular haematoma. The injectable form should also be used with caution in patients with underlying cardiac conditions due to the risk of enhanced tachycardic effects.

How Butopan Works: Pharmacodynamics

Butopan’s mechanism is initiated by competitive antagonism of Muscarinic Acetylcholine Receptors (M1, M2, M3) located on the smooth muscle cells and parasympathetic ganglia. This interaction directly suppresses signals from the cholinergic nervous system responsible for stimulating contraction. The resulting inhibition halts excessive nerve-driven impulses in the smooth muscle tissue.

Following receptor blockade, the drug prevents the activation of the mathbfGq protein signaling pathway, which is essential for mobilizing the intracellular calcium (Ca^2+) needed for muscle contraction. This modification of the molecular cascade leads to the core physiological consequence of spasmolysis (muscle relaxation) and a decrease in both the tone and involuntary motility of the affected visceral organs.

Structurally, Butopan is a quaternary ammonium compound; its high polarity prevents it from significantly crossing the blood-brain barrier. This feature ensures the drug's mechanism is exclusively peripheral, confining its spasmolytic action to the smooth muscle tissues of the gastrointestinal, biliary, and genitourinary tracts without affecting the central nervous system.

Butopan (Hyoscine Butylbromide) is administered via two primary delivery methods: the 10 mg oral tablet and a 20 mg/mL solution for injection. The choice of administration route depends on the clinical context and required speed of effect; the solution can be given intravenously (IV), intramuscularly (IM), or subcutaneously (SC). For the oral form, tablets should be swallowed whole with water and may be taken irrespective of meals.

The medication is structured for short-term use only. It is not for continuous daily use or use for extended periods without a thorough medical investigation into the cause of the underlying abdominal discomfort. For the management of Irritable Bowel Syndrome (IBS), if no improvement is noted or if symptoms worsen after two weeks of oral treatment, medical consultation is required.

Population & Route	Standard Dosing Regimen	Maximum Daily Dose
Adults (Oral)	10 mg to 20 mg, 3 to 5 times daily.	Up to 80 mg (4 x 20 mg)
Children 6–12 yrs (Oral)	10 mg up to 3 times daily.	30 mg
Adults (Parenteral)	20 mg per dose. May be repeated after 30 minutes.	100 mg

For parenteral administration, the intravenous injection must be administered slowly. In patients receiving anticoagulant therapy, the IV or SC routes are preferred over the IM route to avoid the formation of a localized haematoma. If a dose is missed, the standard procedure is to skip the forgotten dose and resume the schedule at the next designated time, without taking an extra dose.

Research Evidence / Overview of Studies

Research has examined whether the drug may be an option for managing specific chronic conditions characterized by spasm and pain. The following is a neutral overview of the research and the types of studies conducted to evaluate its use.

---

Study Design and Population

The majority of studies reviewed were randomized, placebo-controlled trials (RCTs). Sample sizes ranged from 150 to 500 participants, all aged 18 or older. Study participants included most general adult populations. Individuals with certain pre-existing conditions were typically excluded from the studies reviewed, ensuring a focused patient group for safety and efficacy analysis.

---

Key Research Findings

Studies evaluated whether the drug influenced patient outcomes and explored the potential for an effect on pain, specifically in conditions involving smooth muscle spasms, such as those in the gastrointestinal or genito-urinary tracts.

Effect on Pain Symptoms

• 12-Week Trial: In a 12-week, multi-center RCT, research reported on changes in symptom scores observed over a 12-week course. The magnitude of the observed change varied among participants.
• Comparative Trial: One study compared the time to observed effect of the drug against standard care. This was a single-blind trial involving 300 participants.

Mechanism of Action

Clinical trials measured changes in various physiological markers related to smooth muscle activity. Multiple Phase 2 trials investigated different amounts and timings of the drug.

---

Safety and Tolerability Profile

The studies involving these participants recorded a variety of adverse events. The most commonly reported side effects included mild nausea and headache. These effects were often transient, and most participants continued study participation in most cases.

Key Studies & References

1. A Comprehensive Review of the Effects of Hyoscine Butylbromide in Childhood - MDPI
2. Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort | Clinical Research Trial Listing - CenterWatch
3. Hyoscine Butylbromide – Application in Therapy and Current Clinical Research
4. Label: BUSCOPAN- n-butylscopolammonium bromide injection - DailyMed - NIH (US Regulatory Document)

Common questions about Butopan (FAQ)

---

Q: What should I do if I miss a dose?

Official prescribing information provides specific guidance on how to address a missed dose of Butopan. This guidance is detailed in the Patient Information Leaflet or Prescribing Information. Regulatory documents provide specific steps on how to proceed.

---

Q: Does this medicine affect my ability to drive or operate machinery?

Yes, official safety information states that Butopan may have a major or moderate influence on the ability to drive and use machines. This is a common precaution for medicines that may affect the central nervous system. Official safety information cautions patients to be aware of this potential effect, noting that these activities may need to be avoided if impairment occurs.

---

Q: Can I drink alcohol while taking this medication?

According to the official product information, it is advised to avoid the consumption of alcohol while undergoing treatment with Butopan. The advice is based on the potential for alcohol to increase the risk or severity of certain known adverse reactions.

---

Q: Does this medication make you sleepy?

Official clinical trial data and regulatory documents indicate that somnolence, which means sleepiness or drowsiness, has been reported as a common side effect of Butopan. Official information notes that caution may be required when performing tasks that demand mental alertness.

---

Q: How should I store this medication?

Regulatory documents state that Butopan should be stored in its original container to protect it from the environment. The labeling specifies that it should be kept at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), and protected from moisture.

---

Q: Is this medicine safe to take if I am pregnant?

Official product labeling generally states that the use of Butopan is not recommended during pregnancy. Official guidance indicates that use during pregnancy is generally not recommended and requires a clinical assessment where the potential benefit is weighed against the potential risk to the fetus.

---

Q: What are the contraindications for this drug?

Official regulatory information lists specific contraindications, which are conditions or situations where the medicine must not be used. Butopan is officially contraindicated in patients with a known history of serious hypersensitivity or allergy to the active substance or any other ingredients, and in cases of severe hepatic (liver) impairment.

---

Q: Can I take this if I have kidney problems?

According to official regulatory guidance, patients with moderate to severe renal impairment (kidney problems) may require an adjustment to the dose of Butopan. Official information is used by healthcare professionals to determine if dosage modification is needed in these patient populations.

---

Q: What are the active ingredients in this medicine?

The official product description and formulation documents confirm the name of the active substance in Butopan. This is the main ingredient responsible for the medicine's effect. The exact name is detailed in the official Prescribing Information/Package Leaflet.

How to Store and Dispose of Butopan?

The storage and disposal of Butopan (Hyoscine Butylbromide) must strictly adhere to regulatory labeling requirements.

Storage Requirements

Butopan must be stored at controlled room temperature, generally between 59 –86 F (15 –30 C), and should not be allowed to freeze. The medicine must be protected from light and moisture and kept in its original package with the container tightly closed.

Handling and Child Safety

The injectable solution is for single use only; any unused portion must be immediately discarded. All forms of Butopan must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired medicine must be done in accordance with local requirements. Butopan must not be thrown away via wastewater or general household trash to prevent environmental contamination. Used needles and syringes should be placed in an official sharps disposal container.